In an era where the pharmaceutical and biotechnology industries are undergoing rapid transformation, the need for ethical, efficient, and human-relevant testing solutions has become increasingly important. Transcell Biologics is emerging as a disruptive force in this space, combining advanced stem cell science with artificial intelligence to reshape traditional drug and vaccine testing frameworks. With a strong focus on innovation, sustainability, and scientific integrity, the company is building next-generation Biological Foundation Models that aim to eliminate animal testing while enhancing precision and scalability.
Leading this transformation is S. Dravida, Founder & CEO of Transcell Biologics Pvt. Ltd., an entrepreneurial biotech leader with extensive global experience across the USA, Canada, and India. With deep expertise in stem cell technology, biobanking, and commercial product development, she brings a rare blend of scientific acumen and business leadership. A biologist by training, she has been associated with institutions such as the University of North Carolina and the Ottawa Health Research Institute, and holds multiple publications and patents to her credit.
Under her leadership, Transcell Biologics has evolved from a research-focused entity into a fully integrated biotechnology enterprise with a well-balanced portfolio of productised offerings like Digital Animal Replacement Technologies (DART), and intellectual property surrounding the same. She shares insights in this interaction into the company’s evolution, its pioneering approach to ethical biotechnology, and the vision shaping its next phase of growth.
Q. Can you briefly introduce the company and its core offering, along with your future plans and goals?
Ans: Transcell Biologics is a once-in-a-generation biotechnology company delivering breakthrough, cruelty-free solutions for global pharma and biopharma workflows. Headquartered in Hyderabad, the company’s flagship offering is an AI-enabled industrialised, deployable enterprise solution that leverages human stem cell technology for testing drugs and vaccines.
Driven by innovation, Transcell Biologics is developing a portfolio of first- and best-in-class productised offerings powered by its in-house “biobox” platform, which supports discovery, development, and testing of pharmaceutical and biopharmaceutical compositions. At the core of our capabilities is a unique, research-grade human biosamples vault that enables hypothesis-driven research aimed at addressing some of the world’s most urgent and complex medical challenges. Over time, we have evolved from a small R&D lab into an organisation with in-house developed specialised, defensible offerings, while intellectual property continues to serve as the foundational bedrock of our growth.
As we expand globally, our goal is to position Transcell Biologics at the forefront of ethical progress in the pharmaceutical and biotechnology industries. Our AI-enabled, non-animal testing platform, Bio-FMs, represents a transformative shift toward more humane, sustainable, and scientifically robust practices. We envision a future where medical breakthroughs are achieved without reliance on animal models. By integrating AI with human stem cell technology, we aim to empower the industry to adopt a new gold standard in testing, reducing ethical dilemmas while improving precision and predictability.
Beyond laboratories, this shift has broader implications; it fosters a culture of responsible innovation, inspires future generations of scientists, and contributes to building a more affordable healthcare ecosystem. Our long-term vision is to champion this Made-in-India innovation globally and create a lasting legacy of positive impact.
Q. What makes your innovation unique compared to others in the industry?
Ans: Innovative testing strategy using relevant human MicroPhysiological Platforms configured on stem cell units is revolutionising drug and vaccine development by ensuring reliability and effectiveness in results. This approach fully aligns with global regulations, including the FDA Modernisation Act 3.0, making it a compliant choice for the pharmaceutical industry. The technology seamlessly integrates into existing bio and pharma workflows, supported by AI-driven automation that enhances the reliability and efficiency of bioassay implementation. By providing human-like responses through stem cell-based systems, the solution delivers relevant insights while focusing on efficiency, reducing disruption, and increasing precision in testing protocols. Moreover, this comprehensive strategy promotes ethical practices by offering cruelty-free alternatives to traditional animal testing, paving the way for a more humane approach to biomedical research.
Q. What challenges have you overcome in your journey so far?
Ans: The journey has been both challenging and rewarding. One of the most significant hurdles was navigating financial constraints, which required a high degree of resourcefulness and strategic prioritisation to deliver meaningful impact with limited resources. Building a strong and capable team was another challenge, particularly in a rapidly evolving sector that demands diverse skill sets and interdisciplinary collaboration.
Scaling operations continue to present their own complexities, requiring adaptability, long-term vision, and careful execution. Each of these challenges, however, has played a crucial role in shaping our resilience and strengthening our organisational foundation. They have also reinforced the importance of perseverance, innovation, and staying aligned with our core mission.
Q. What changes would you like to see in your segment or the industry?
Ans: The pharmaceutical and biotechnology industry stands at a critical juncture. To drive meaningful progress, there must be a stronger emphasis on decision-making grounded in scientific evidence, along with a greater willingness to take calculated risks. Innovation often requires stepping beyond conventional boundaries, and fostering such a mindset is essential for long-term advancement.
Encouraging the adoption of ethical and sustainable practices, particularly in testing methodologies, is equally important. As the industry evolves, aligning innovation with responsibility will be key to building trust, improving outcomes, and ensuring a more progressive future.
Q. Your leadership mantra?
Ans: Speed matters. Science can’t wait. Be authentic!
Disclaimer: This is a sponsored article. All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Outlookindia.com does not take any liability for the same. Using of any information provided in the article is solely at the viewers’ discretion.
